1,2-Pyrrolidinecarboxylic Acid 5-Oxo,1-(Tertbutyl)-2-Methylester

Methyl (2S)-1-(2-methyl-2-propyl)-5-oxopyrrolidine-2-carboxylate—routinely referenced as methyl N-tert-butyl pyroglutamate—functions as a cyclic, non‑racemising chiral template across a narrowly defined set of cGMP‑governed synthetic sequences. Introduction of the 5-oxopyrrolidine scaffold into a production‑scale lithium enolate alkylation demands that the jacket‑chilled −78 °C threshold be maintained with a deviation of no more than ±3 °C, a window enforced by the measured half‑life of the corresponding (Z)‑enolate intermediate of <18 min at −65 °C in anhydrous THF/tetramethylenediamine mixtures. Under these conditions the addition ratio of the ester to lithium diisopropylamide—freshly titrated against n‑butyllithium‑hexane standard to a molarity of 1.05–1.15 M—is held at 1.00:1.10 mol/mol, a stoichiometric offset that compensates for residual moisture quantified by Karl Fischer titration (ASTM E203‑16) at <50 ppm H₂O. The alkylation reactor train, typically a 500 L glass‑lined vessel coupled to a ThermoHaake TIC‑316 circulation system, is pre‑dried with THF azeotrope stripping until headspace dew point reads ≤−85 °C (Vaisala DMT143). After the electrophile—frequently a benzyl chloromethyl ether or an allyl halide—is metered 0.95 eq relative to the enolate over 45–60 min, the reaction mass is quenched with 10 % aqueous ammonium chloride pre‑cooled to 0 °C and simultaneously extracted into methyl tert‑butyl ether. The organic phase undergoes a pH‑controlled back‑extraction with 0.5 M KHSO₄ to remove diisopropylamine, followed by neutralisation and continuous‑feed vacuum crystallisation from n‑heptane/ethyl acetate (4:1 v/v) at −10 °C. The diastereomeric outcome is monitored by chiral SFC (USP <621> System Suitability, Chiralpak IA column, 3.0 mL min⁻¹ CO₂/methanol 85:15) to confirm ≥99.5 % de. The isolated alkylated product undergoes sequential deprotection: tert‑butylamide hydrolysis with 85 % formic acid at 50 °C for 8 h, followed by ester saponification in 1.0 M LiOH‑THF‑H₂O (2:2:1) affording the unprotected (S)‑α‑monosubstituted amino acid in ≥98 % isolated yield. The terminal deliverable is an API starting material incorporating a quaternary‑α‑amino acid motif, registered under a Type II drug master file and conforming to ICH M7 (DNA‑reactive impurity thresholds at <1.5 µg day⁻¹) as well as ICH Q3C residual solvent limits for THF (≤720 ppm) and n‑heptane (≤5000 ppm).

What Limits Continuous‑Flow Enolate Trapping of the Pyroglutamate System for the Manufacture of (2S,3S)‑β‑Substituted Amino Alcohols?

The adaptation of batch lithiation‑alkylation to a Corning® Advanced‑Flow G1 reactor for kilogram‑per‑day output reveals a critical heat‑transfer bottleneck arising from the instantaneous exotherm (ΔH_r measured by RC1 calorimetry, −98 kJ mol⁻¹) when the LDA stream contacts the dissolved pyroglutamate at −40 °C. To avoid hot‑spot‑induced racemisation at the C‑2 α‑carbon—where a temperature spike of +12 °C inside the glass fluidic module reduces enantiomeric purity by 0.7 % ee per minute—the mixing point is split into four successive sub‑ambient modules each maintained at −65 °C by a Julabo F‑84 cryostat delivering 27 L min⁻¹ of Syltherm XLT. The formulation charges the template at a concentration of 0.45 M in THF‑toluene (7:3 v/v) and the LDA at 0.55 M, with a molar feed ratio of 1.00:1.15. The industry‑accepted compliance framework for this intermediate class includes adherence to the FDA 21 CFR § 210.1 manufacturing practice standard, supplemented by EU GMP Part II § 19 for control of recovered solvents. Downstream, the enolate stream is reacted with (S)‑epichlorohydrin (1.05 eq) in a residence‑time module of 2.8 mL to give the spiro‑epoxide intermediate, which is subsequently opened with benzylamine under microwave‑assisted heating (100 W, 120 °C, 20 min) to generate the (2S,3S)‑amino diol scaffold. The final product type is an enantiomerically pure β‑hydroxy‑α‑amino alcohol building block used in parenteral antithrombotic agents; its peptide coupling compatibility is documented against EP 10.0 monograph 2.2.46 for chiral purity and residual metal catalysts (ICP‑MS following USP <233>, Pd < 10 ppm, Li < 50 ppm).

The employment of methyl N-tert‑butyl pyroglutamate as a chiral auxiliary in the kilogram‑scale preparation of a 2‑aryl‑1,4‑benzodiazepine‑2‑carboxylic acid prodrug—a non‑sedating anxiolytic candidate—commences with the preparation of the template‑derived imine. The ester is reduced with LiAlH₄ (2.0 eq, 0 °C to 25 °C in anhydrous diethyl ether, ISO 6353‑1 reagent grade) to the corresponding alcohol, which is immediately oxidised under Pfitzner‑Moffatt conditions to the aldehyde. Condensation with (R)‑phenylglycinol (1.0 eq) in the presence of molecular sieves 4 Å (≥85 % activity) furnishes the Schiff base. The addition ratio of the chiral template to the 2‑aminobenzophenone precursor is 1.00:1.30 mol/mol, ensuring complete diastereocontrol in the subsequent intramolecular cyclisation that proceeds at 55 °C in cyclopentyl methyl ether over 18 h. Process‑scale equipment—a Büchi GlasUster 160 L pressure reactor with retreat‑blade impeller—conducts the ring‑closure under positive nitrogen pressure (0.2 bar) to mitigate oxidative by‑product formation. After extractive work‑up in ethyl acetate/water, the diastereomeric purity is verified against a reference standard by achiral‑chiral coupled HPLC (Agilent 1260 Infinity II, Poroshell 120 EC‑C18 → Chiralcel OJ‑H, UV _254 nm) yielding a d.r. of 98.2:1.8. Detachment of the auxiliary is effected with 6 M HCl in isopropanol at reflux (82 °C, 6 h), and the isolated (S)‑benzodiazepine carboxylic acid is recrystallised from water‑isopropanol to ICH Q3C‑compliant residual isopropanol levels (≤5000 ppm). The delivery format is a lyophilised, single‑isomer API intermediate supplied with a full E&L study in accordance with USP <1663> and certificate of analysis referencing European Pharmacopoeia monographs 2‑[5‑(dimethylamino)ethyl]‑2‑arylpentanoate analogues.

Synthesis of Chiral N‑Heterocyclic Carbene Ligand Precursors via Diastereoselective Alkylation of the Trans‑Configured Enolate

The methyl ester serves as the enantiodetermining substrate in a modular route to imidazolinium‑fused pyrazine ligands exploited in palladium‑catalysed α‑arylation of acetophenone derivatives. In a dedicated isolator facility (ISO 14644‑1, Class 7, operating at 20 Pa positive differential), an ethereal solution of the pyroglutamate (0.80 M in 2‑methyltetrahydrofuran) is treated with NaHMDS (1.25 eq, 1.0 M in THF) at −50 °C to direct enolate geometry toward the thermodynamically favoured trans‑isomer, a profile confirmed by quench‑NOE experiments on an ¹H‑400 MHz spectrometer. The enolate is then alkylated with 2‑chloro‑3‑(1‑pyrrolidinyl)quinoxaline (0.95 eq) dispensed via peristaltic pump, and the resulting C‑alkylated lactam is hydrogenated with Raney‑Ni 2800 (W.R. Grace, 5 wt % loading, slurry in water) at 40 psi H₂ and 50 °C for 24 h to reduce the heterocycle. Subsequent lactam ring‑opening with 3.0 M HCl‑MeOH generates the diamino hydrochloride, which is immediately cyclised with triethyl orthoformate (3.0 eq) and NH₄BF₄ to form the imidazolinium salt. The overall process operates at a scale of 8–12 kg per batch, with the critical quality attribute being residual chloride measured by potentiometric titration (USP <221>, acceptance criterion ≤0.05 %). Application‑specific purity is benchmarked against the ASTM D5388‑21 standard for vibrational circular dichroism, which validates the absolute configuration of the ligand after complexation with Pd(0). The commercial terminal product is a pre‑ligand kit containing the NHC·HBF₄ salt and Pd₂(dba)₃ at a stoichiometric ratio of 1.0:0.50 mol/mol, deployed in generic API routes for angiotensin II receptor antagonists.

To access enantiopure (S)‑3‑aminopyrrolidine‑3‑carboxylic acid, a constrained β‑amino acid requested in late‑stage optimisation of integrin inhibitors, the pyroglutamate template is first converted to the enol triflate via treatment with Comins’ reagent (2‑[N,N‑bis(trifluoromethylsulfonyl)amino]‑5‑chloropyridine, 1.2 eq) and KHMDS at −78 °C. The subsequent Negishi coupling with N‑Boc‑3‑iodoazetidine utilises a Pd‑XPhos‑G2 pre‑catalyst (loading 0.8 mol %) in THF/NMP 9:1 at 65 °C for 5 h. A key operational constraint arises from the sensitivity of the vinyl triflate to trace water, which leads to protiodestannylation by‑products; therefore the batch is processed under a recirculating nitrogen purge (dew point ≤ −78 °C) and every reactor port is fitted with a PTFE‑sealed septum. The addition ratio of organozinc reagent to triflate is strictly maintained at 2.2:1.0 mol/mol to drive conversion past 85 %, after which the unreacted Zn species are removed by a 15 % aqueous NH₄OH wash. Global regulatory alignment for this intermediate—a starting material for a Phase III oncology candidate—requires a Broker’s declaration to REACH Annex VI (EC No. by‑product listing) and an ISO 13485:2016 risk‑managed quality plan for custom synthesis. The manufacturing process is validated against ICH Q2(R2) for related substances; the HPLC method employs a gradient of 0.10 % trifluoroacetic acid in acetonitrile‑water with a Quantum‑Triart LC‑MS column (2.7 µm particles) and achieves a reporting threshold of 0.05 area % for the des‑Boc analogue. The isolated product is the di‑tert‑butoxycarbonyl protected amine, supplied as a white lyophilised powder certified for residual palladium by GF‑AAS (USP <852>) at ≤10 ppm.

When the Tert‑Butyl Moiety Is Engineered as a Process‑Cleavable Solubility Switch in Solid‑Phase Peptide Mimetic Assembly

The incorporation of (S)‑N‑tert‑butyl‑5‑oxoproline methyl ester into a Fmoc‑SPPS strategy enables the on‑resin construction of a 15‑mer opioid peptide analogue containing a conformationally‑locked pyroglutamyl‑mimetic residue. The ester is first saponified to the free acid (LiOH·H₂O, 1.0 eq, THF‑H₂O 3:1, 0 °C, 2 h) and coupled to Wang resin pre‑loaded with H‑Lys(Boc)‑OH using HBTU/DIEA activation (molar ratio of acid to resin substitution: 3.0:1.0). The resin‑bound peptide elongation proceeds under standard Fmoc cycles, with the tert‑butyl group on the lactam nitrogen serving as a temporary masking element that prevents premature diketopiperazine formation during the first two couplings; it is selectively removed with 50 % TFA in DCM containing triisopropylsilane (5 %) and water (2 %) during the final global cleavage. This process is executed on a Aapptec Apex 396 automatic peptide synthesiser with a reactor size of 50 mmol, utilising a reaction vessel thermostatted at 22 ± 1 °C. Compliance with USP <1503> for synthetic peptide purity requires monitoring by UPLC‑QToF, and the presence of the non‑proteinogenic pyroglutamyl surrogate necessitates an in‑house specific‑impurity profile validated according to ICH Q3A‑Q3B guidelines, with a specification for the epimerised peptide of <0.50 % relative peak area. The delivered pharmaceutical intermediate—a tert‑butyl‑deprotected linear peptide bearing an N‑terminal pyroglutamic acid lactam—is precipitated from cold diethyl ether, triturated, and vacuum‑centrifuged (GeneVac EZ‑2 Plus, 45 °C, 5 mbar) to a residual TFA content of <0.10 % w/w. The target client product is a lyophilised study‑grade peptide for a mu‑opioid receptor programme, requiring biocompatibility data referencing USP <87> for endotoxin (<0.10 EU mg⁻¹).

Direct resolution of racemic 2‑arylpropionic acids using a stoichiometric quantity of the pyroglutamate‑derived chiral selector is practiced only in those limited instances where the free acid crystallises as a stable diastereomeric salt with a ΔpK_a difference of <0.2 units. In such a protocol, the methyl ester is first reduced with NaBH₄‑I₂ in diglyme to yield the corresponding (S)‑N‑tert‑butyl‑2‑hydroxymethyl pyrrolidine, which is subsequently esterified with 4‑chlorobenzoic acid to install a UV‑chromophore for process‑scale HPLC monitoring. The resolution is conducted in acetone‑water (95:5 v/v) at 55 °C, and the weight‑based incorporation of the resolving agent to the racemate is 0.55:1.00 (corresponding to a molar ratio of 0.50:1.00), deliberately below the theoretical amount to favour anti‑selective precipitation of the less‑soluble (S)‑acid:selector salt. The downstream filtration utilises a Rosemund‑type agitated nutsche filter‑dryer under 0.5 bar nitrogen, washed with 2 × 1.0 L chilled acetone. Recovery of the chiral auxiliary is achieved by a pH‑swing extraction—salification of the (R)‑acid liquor with aqueous NaOH to pH 11 back‑extracts the amine selector into MTBE with ≥92 % efficiency. This resolution unit complies with ASTM E260‑23 for peak purity of the recovered acid and selector, and the permitted application is as a reference standard production for a non‑marketed NSAID analogue where the API specification in accordance with USP <1066> for specific rotation is fixed at [α]²⁰_D = +54.5 ± 0.3° (c = 1.0, MeOH).